Rigel has a global exclusive license agreement with Eli Lilly for Rigel’s RIPK1 inhibitor programs in all indications.
This collaboration includes the development and commercialization of ocadusertib (previously LY3871801/R552), a potent and selective receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor, for all indications including autoimmune and inflammatory diseases.
Enrollment in Lilly's Phase 2a clinical trial (NCT05848258) studying ocadusertib in adult patients with moderately to severely active rheumatoid arthritis is ongoing. Pursuant to the collaboration, Lilly also leads all preclinical and clinical development of brain penetrating RIPK1 inhibitors in central nervous system (CNS) diseases. Selection of RIPK1 inhibitor candidates that cross the blood-brain barrier for CNS diseases is underway.
Rigel received an upfront payment, and is eligible for development, regulatory, and commercial milestone payments, and tiered royalty payments on any future net sales of any products emerging from the collaboration.